Cargando…
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that was first described in 1980. It has been prevalent and on the rise for many years and is associated with other metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM). NAFLD can be best described as...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626571/ https://www.ncbi.nlm.nih.gov/pubmed/34870138 http://dx.doi.org/10.1016/j.metop.2021.100149 |
_version_ | 1784606682173669376 |
---|---|
author | Zarghamravanbakhsh, Paria Frenkel, Michael Poretsky, Leonid |
author_facet | Zarghamravanbakhsh, Paria Frenkel, Michael Poretsky, Leonid |
author_sort | Zarghamravanbakhsh, Paria |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that was first described in 1980. It has been prevalent and on the rise for many years and is associated with other metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM). NAFLD can be best described as a metabolic dysfunction that stems from insulin resistance-induced hepatic lipogenesis. This lipogenesis increases oxidative stress and hepatic inflammation and is often potentiated by genetic and gut microbiome dysfunction. As NAFLD progresses from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis and hepatocellular carcinoma (HCC), the odds of complications including cardiovascular disease (CVD), chronic kidney disease (CKD), and overall mortality increase. The aim of this review is to describe the metabolic causes and consequences of NAFLD while examining the risks that each stage of NAFLD poses. In this review, the etiology of “lean” NAFLD, the impact of obesity, T2DM, genetics, and microbiome dysbiosis on NAFLD progression are all explored. This review will also discuss the core issue behind the progression of NAFLD: insulin resistance (IR). Upon describing the causes and consequences of NAFLD, the effectiveness of diet modification, lifestyle changes, and glucagon-like peptide 1 receptor (GLP-1) agonists to retard NAFLD progression and stem the rate of complications is examined. |
format | Online Article Text |
id | pubmed-8626571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86265712021-12-02 Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) Zarghamravanbakhsh, Paria Frenkel, Michael Poretsky, Leonid Metabol Open Articles from the NAFLD: from Molecular Basis to Therapeutic Advances Special Issue Nonalcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that was first described in 1980. It has been prevalent and on the rise for many years and is associated with other metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM). NAFLD can be best described as a metabolic dysfunction that stems from insulin resistance-induced hepatic lipogenesis. This lipogenesis increases oxidative stress and hepatic inflammation and is often potentiated by genetic and gut microbiome dysfunction. As NAFLD progresses from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis and hepatocellular carcinoma (HCC), the odds of complications including cardiovascular disease (CVD), chronic kidney disease (CKD), and overall mortality increase. The aim of this review is to describe the metabolic causes and consequences of NAFLD while examining the risks that each stage of NAFLD poses. In this review, the etiology of “lean” NAFLD, the impact of obesity, T2DM, genetics, and microbiome dysbiosis on NAFLD progression are all explored. This review will also discuss the core issue behind the progression of NAFLD: insulin resistance (IR). Upon describing the causes and consequences of NAFLD, the effectiveness of diet modification, lifestyle changes, and glucagon-like peptide 1 receptor (GLP-1) agonists to retard NAFLD progression and stem the rate of complications is examined. Elsevier 2021-11-16 /pmc/articles/PMC8626571/ /pubmed/34870138 http://dx.doi.org/10.1016/j.metop.2021.100149 Text en © 2021 Northwell Health https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles from the NAFLD: from Molecular Basis to Therapeutic Advances Special Issue Zarghamravanbakhsh, Paria Frenkel, Michael Poretsky, Leonid Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) |
title | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) |
title_full | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) |
title_fullStr | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) |
title_full_unstemmed | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) |
title_short | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) |
title_sort | metabolic causes and consequences of nonalcoholic fatty liver disease (nafld) |
topic | Articles from the NAFLD: from Molecular Basis to Therapeutic Advances Special Issue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626571/ https://www.ncbi.nlm.nih.gov/pubmed/34870138 http://dx.doi.org/10.1016/j.metop.2021.100149 |
work_keys_str_mv | AT zarghamravanbakhshparia metaboliccausesandconsequencesofnonalcoholicfattyliverdiseasenafld AT frenkelmichael metaboliccausesandconsequencesofnonalcoholicfattyliverdiseasenafld AT poretskyleonid metaboliccausesandconsequencesofnonalcoholicfattyliverdiseasenafld |